Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 1, 2012

Targovax Raises $2.2M to Progress Vaccine into Phase II Pancreatic Cancer Trials

  • Norwegian firm Targovax raised NOK 13 million (about $2.2 million) in a series A round of financing to progress its lead anticancer vaccine TG01 into Phase II clinical development as a treatment for pancreatic cancer. The investment consortium included the Radium Hospital Research Foundation, Birk Venture, RO Invest, and existing owners. The new funding follows just a couple of months after Targovax won an Innovation Norway grant of NOK 9 million.

    Targovax was established in October 2010 to develop the TG01, a peptide vaccine targeting Ras gene mutations. The vaccine originates from research carried at The Radium Hospital and Norsk Hydro in the late 1990s, and initial trials in patients. Targovax says the latest funding will allow it to manufacture first GMP batches and initiate a Phase II study evaluating TG01 as an adjuvant treatment for pancreatic cancers in patients who have undergone surgery. Patient recruitment is expected to start by the end of 2012. 



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »